We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) closed at $518.18 in the latest trading session, marking a +0.57% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.12%. At the same time, the Dow added 0.13%, and the tech-heavy Nasdaq lost 4.09%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 2.74% over the past month, lagging the Medical sector's loss of 2.13% and the S&P 500's gain of 3.98% in that time.
Wall Street will be looking for positivity from Thermo Fisher Scientific as it approaches its next earnings report date. On that day, Thermo Fisher Scientific is projected to report earnings of $5.43 per share, which would represent a year-over-year decline of 1.45%. Our most recent consensus estimate is calling for quarterly revenue of $10.99 billion, up 0.21% from the year-ago period.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $23.69 per share and revenue of $45.3 billion. These results would represent year-over-year changes of +1.94% and +0.86%, respectively.
Investors might also notice recent changes to analyst estimates for Thermo Fisher Scientific. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.02% lower within the past month. Thermo Fisher Scientific currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Thermo Fisher Scientific currently has a Forward P/E ratio of 21.75. Its industry sports an average Forward P/E of 29.54, so we one might conclude that Thermo Fisher Scientific is trading at a discount comparatively.
It is also worth noting that TMO currently has a PEG ratio of 2.56. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.55 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
Thermo Fisher Scientific (TMO - Free Report) closed at $518.18 in the latest trading session, marking a +0.57% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.12%. At the same time, the Dow added 0.13%, and the tech-heavy Nasdaq lost 4.09%.
Heading into today, shares of the maker of scientific instrument and laboratory supplies had lost 2.74% over the past month, lagging the Medical sector's loss of 2.13% and the S&P 500's gain of 3.98% in that time.
Wall Street will be looking for positivity from Thermo Fisher Scientific as it approaches its next earnings report date. On that day, Thermo Fisher Scientific is projected to report earnings of $5.43 per share, which would represent a year-over-year decline of 1.45%. Our most recent consensus estimate is calling for quarterly revenue of $10.99 billion, up 0.21% from the year-ago period.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $23.69 per share and revenue of $45.3 billion. These results would represent year-over-year changes of +1.94% and +0.86%, respectively.
Investors might also notice recent changes to analyst estimates for Thermo Fisher Scientific. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.02% lower within the past month. Thermo Fisher Scientific currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Thermo Fisher Scientific currently has a Forward P/E ratio of 21.75. Its industry sports an average Forward P/E of 29.54, so we one might conclude that Thermo Fisher Scientific is trading at a discount comparatively.
It is also worth noting that TMO currently has a PEG ratio of 2.56. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.55 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.